A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of Three Consistency Lots and a high Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults

Project: Other project

StatusFinished
Effective start/end date8/4/159/30/18

Funding

  • Merck Sharp & Dohme Corporation: $96,966.24